Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The Netrin-1/DCC guidance system: dopamine pathway maturation and psychiatric disorders emerging in adolescence


Axon guidance molecules direct growing axons toward their targets, assembling the intricate wiring of the nervous system. One of these molecules, Netrin-1, and its receptor, DCC (deleted in colorectal cancer), has profound effects, in laboratory animals, on the adolescent expansion of mesocorticolimbic pathways, particularly dopamine. Now, a rapidly growing literature suggests that (1) these same alterations could occur in humans, and (2) genetic variants in Netrin-1 and DCC are associated with depression, schizophrenia, and substance use. Together, these findings provide compelling evidence that Netrin-1 and DCC influence mesocorticolimbic-related psychopathological states that emerge during adolescence.


The human brain is interconnected by an estimated 10 million km of neurites [1]. The specific routes taken are choreographed by a surprisingly small number of axon guidance molecules [2]. In this review, we summarize evidence that recently identified mutations and common variants of genes encoding the guidance cue Netrin-1 and its receptor, DCC (deleted in colorectal cancer), affect the adolescent expansion of mesocorticolimbic dopamine pathways and vulnerability to putative mesocorticolimbic-related psychiatric disorders.

Mesocorticolimbic dopamine anatomy and psychiatric disorders

The primate mesocorticolimbic dopamine system shares many features with the homologous pathways in rodents. As in rodents, primate dopamine cells project from the upper brainstem to the dorsal striatum and multiple cortical and subcortical limbic regions [3, 4]. These latter targets include the ventral striatum (nucleus accumbens (NAcc), olfactory tubercle), septum, hippocampus, amygdala, and cortical regions, particularly the prefrontal (PFC), cingulate, and perirhinal cortices. Primates and rodents both have descending glutamatergic and GABAergic projections from the anterior cingulate and orbital frontal cortices to several limbic and midbrain regions, including the ventral striatum and the dopamine cell body regions, the substantia nigra (SN) and ventral tegmental area (VTA) [3, 5]. In both rodents and primates, the density of mesocortical dopamine fibers increases dramatically from adolescence to adulthood [6, 7]. This process, at least in rodents, results from dopamine axons continuing to grow beyond the NAcc to the PFC across adolescence [8]. Compared to rodents, primate cortical dopamine projections are more widespread [9], innervating the entire cortical mantle, albeit more to anterior than posterior regions [10, 11]. Subcortical dopamine axons are often myelinated in primates, a feature not seen in rodents [10].

Disturbances to mesocorticolimbic development have been proposed to contribute to multiple psychiatric disorders. Consistent with this hypothesis, dopamine neurotransmission and mesocorticolimbic functional connectivity (the degree to which functional magnetic resonance imaging (fMRI) blood oxygen level-dependent (BOLD) signals from disparate brain regions are temporally correlated) are altered in the mesocorticolimbic system in schizophrenia [12], stimulant drug addiction [13, 14], and depression [15, 16], each of which begins to emerge in adolescence [17, 18]. The proposal here is that DCC-mediated Netrin-1 signaling alterations might be an important contributing factor [6, 7, 19] (Fig. 1).

Fig. 1

a DCC-mediated Netrin-1 connectivity-related processes. Throughout adolescent brain development, target recognition, axon arborization, and synapse formation are ongoing including dopamine axon targettting, long distance axonal growth, and synaptogenesis by mesocorticolimbic dopamine axons. Green gradients indicate Netrin-1 and the depicted axons  express DCC. b Dcc Mutation Behavioral Effects in Mice. Ages, in post-natal days (P), and periods (early adolescence, mid adolescence, and adulthood) at which stimulant drug-induced effects on reward and information processing emerge in Dcc haploinsufficient mice. The effects are in green, based on studies of Dcc haploinsufficient mice [6, 7]. c Age of Onset of DCC-implicated Psychiatric Disorders. The DCC-implicated psychiatric disorders, major depressive disorder, schizophrenia, and substance use disorder, begin to emerge in adolescence. The interquartile ranges (25th to 75th percentiles) are indicated in green. The median ages of onset for major depressive disorder, schizophrenia, and substance use disorder are 32, 23, and 20, respectively. Data to construct the figure were obtained from a U.S. survey and an international review [17, 18]

Axon guidance

The axon guidance properties of Netrin-1 and its receptor, DCC, are shared by a larger class of proteins which operate according to the following general mechanisms. During neurodevelopment, axon navigation is directed by extracellular axon guidance cues, which attract or repel growing axons by inducing molecular changes in their growth cones [2]. Growth cones are versatile structures with actin-based finger-like extensions (filopodia) and protruding sheets (lamellipodia) in their peripheral domains and microtubules in their central domains. Guidance cues induce elongation, retraction, or turning of growth cones, by altering the relative rates of polymerization and depolymerization in actin filaments as well as changes in microtubule stabilization of the growth cone’s cytoskeletal proteins, including actin filaments and microtubules [20]. These processes play a critical role in the organization of brain connectivity and are coordinated by a small number of guidance cue families, including the netrins, slits, semaphorins, and ephrins [2, 21]. There are many members of these families as well as splice variants [2, 21]. While the present review focusses on Netrin-1 and its receptor, DCC, there are additional Netrin-1 receptors including Neogenin [22], uncoordinated 5 homologues (UNC5-H) [23], and Down syndrome cell adhesion molecule (DSCAM) that contribute to the orchestration of neuronal networks [24]. Furthermore, in addition to guidance cue systems, cell adhesion molecules, such as neural cell adhesion molecules (NCAM) [25] and cadhedrins [26], as well as growth factors, also play critical roles in brain connectivity processes (i.e., synapse formation [27], axon branching [28], and axon guidance [29]).

Netrin-1 and its DCC receptor

Netrin-1 is a mammalian laminin-related diffusible molecule that interacts attractively or repulsively with several receptors, including DCC [30]. These effects of Netrin-1 play a well-documented role in axonal pathfinding, an evolutionarily conserved process demonstrated in several species, including Drosophila [31], C. elegans [32], and rodents [6]. The role of netrin and its receptors continues beyond the laying down of pathway connectivity. Indeed, once axons reach their intermediate or final targets, Netrin-1 participates in connectivity-related processes, including target recognition, axon branching, synaptogenesis, and synaptic plasticity [11, 30, 32, 33].

DCC receptors are part of the immunoglobulin superfamily and their extracellular domains are composed of four immunoglobulin domains, in addition to six fibronectin type III repeats [34]. The fourth, fifth, and sixth fibronectin type III repeats constitute the binding sites for Netrin-1 [35]. In humans and rodents, the DCC gene is located on chromosome 18 and comprises 29 exons [36]. The first demonstration of DCC’s role in axon guidance was in commissural fibers of the developing neural tube [37], but DCC’s role is not restricted to these fibers or to this early stage. Instead, DCC remains expressed across the lifespan throughout the nervous system [38,39,40]. DCC and Netrin-1 are highly expressed in dopamine cell bodies and terminal regions, including the SN, VTA, striatum, hippocampus, and cerebral cortex, in both rodents and humans [38,39,40,41,42,43,44,45].

Mice bred for Dcc haploinsufficiency (+/−) have altered adolescent development of mesocorticolimbic dopamine neurons affecting dopamine transmission and dopamine-related behaviors in adulthood [6, 7]. Adult Dcc+/− mice exhibit increased dopamine axon innervation, dopamine presynaptic sites, and amphetamine-induced dopamine release in the PFC. In comparison, in the NAcc, there are decreases in dopamine varicosities and amphetamine-induced dopamine release [8, 42, 45, 46]. The latter effects result from ectopic growth of mesolimbic dopamine axons to the PFC, a concomitant increase in mesocortical dopamine synapses [8], function [47], and augmented cortical inhibitory control over the responsiveness of mesolimbic dopamine neurons [48]. These changes are concordant with the findings that, as adults, but not as adolescents, Dcc+/− mice display multiple alterations to dopamine-related behaviors, including diminished sensitivity to the effects of stimulant drugs (cocaine, amphetamine, methamphetamine) on locomotor activity, sensorimotor gating, conditioned place preference, and intracranial self-stimulation [6, 42, 49, 50]. These behavioral effects have been observed primarily under pharmacological challenge conditions but drug-free adult DCC-deficient mice exhibit reduced impulsivity [8] and attend less to a novel object in the presence of a familiar object [51]. These altered drug responses might be specific to stimulants, given that no differences in conditioned place preference responses are observed to either morphine or ethanol between Dcc haploinsufficient mice and controls (Personal Communication; Flores, Keifer, Darq and Nouel).

Behavioral and neurochemical effects of DCC haploinsufficiency are mirrored by Netrin-1 haploinsufficiency. In adulthood, but not in adolescence, Netrin-1 haploinsufficient mice exhibit increased medial PFC (mPFC) dopamine concentrations and reduced sensitivity to the behavioral effects of amphetamine [48]. Finally, adolescent amphetamine administration alters the expression of both DCC in dopamine neurons and Netrin-1 in the NAcc and mPFC [52].

In the following sections, we collate the evidence that similar DCC and Netrin-1 related effects occur in humans, influencing susceptibility to mood disorders, psychosis, and addictions. As described above, specifically during adolescence, DCC and Netrin-1 mediate dopamine axon targeting in rodents. These processes coincide with changing levels of a microRNA which suppresses DCC expression, miR-218 [7]. In comparison, directly testing temporal effects is generally not possible in human genetic association studies, given that the polymorphisms or mutations are present throughout the lifespan. Nonetheless, as depicted in Fig. 1, the observation that the psychiatric disorders associated with DCC and Netrin-1 polymorphisms begin to emerge in adolescence raises the tantalizing possibility that the processes follow a parallel neurodevelopmental pathway.

Human genetic investigations of DCC


Several studies have linked DCC polymorphisms with schizophrenia. In a candidate gene study, comprising 556 schizophrenia patients and 208 healthy controls, a SNP (rs2270954) in DCC was found to be nominally associated with schizophrenia. It was postulated that because this SNP is within the regulatory 3′ untranslated region (UTR), it may alter DCC mRNA stability and consequently levels of DCC protein translation [53]. Given that the 3′UTR region contains microRNA (miRNA) binding sequences, the identified SNP may disrupt miRNA binding, potentially increasing DCC expression by preventing DCC mRNA transcript degradation and/or translation inhibition [54, 55].

A second candidate gene study of 454 patients with schizophrenia and 486 healthy controls reported a nominal association with a DCC SNP (rs2229080) on exon 3 [56]. The authors also found evidence that rs2229080 induces a protein structural change and, according to in silico analyses, alters splicing regulation. Moreover, the authors noted that rs2229080 is a known target of loss of heterozygosity (LOH) and that such LOH is associated with reduced DCC expression [57]. Thus, if the rs2229080 risk allele disrupts the LOH target site (which downregulates DCC), the authors proposed that the risk allele would result in increased DCC expression, changing mesocorticolimbic dopamine development and ultimately contributing to the schizophrenia phenotype [56]. Subsequently, a much larger genome wide association study (GWAS), applying a false discovery rate (FDR) correction, found that an intronic locus of DCC (rs4632195) is associated with schizophrenia (n = 82,315) [58]. A mechanism regarding predicted expression outcomes remains to be determined for this SNP. Most recently, by applying next-generation sequencing, which sequences the entire genome and can detect rare variants, loci in five genes, including DCC, were shared among three family members exhibiting atypical psychosis [59].


Over the past six years, there has been rapidly accumulating evidence that both genetic variants and other factors that alter DCC expression also affect susceptibility to mood dysregulation and suicide. Two independent studies from our group, in a discovery and replication cohort, have demonstrated that depressed suicide completers exhibit elevated DCC mRNA expression in the PFC, and a corresponding downregulation of the DCC miRNA repressor, miR-218 [54, 60]. Moreover, a genome-wide investigation of differential gene expression in blood, applying a Bayesian approach, identified 165 differentially expressed genes in major depressive disorder, including overexpression of DCC [61]. Further strengthening these findings is a blood-derived methylome-wide association study (MWAS) of 812 patients with depression and 320 controls, which found associations between methylation sites in DCC and depression [62]. Notably, while there is evidence of general concordance between DNA methylation across blood and brain tissue, there are exceptions [63], and this is a limitation of the study.

GWAS research has identified an intronic DCC SNP (rs4542757) associated with depressive symptoms (n = 3138) [64]. Although this effect did not achieve genome-wide significance and was not identified in a replication sample, the GWAS study was likely underpowered [64]. A larger GWAS study (n = 161,460) identified an association between depressive symptoms and an intronic DCC SNP, rs62100776 [65]. Moreover, using pathway analyses in two independent samples (n = 6455, n = 18,759), FDR-corrected associations between depression and a Netrin-1 signaling pathway were identified, comprising SNPs from multiple genes involved in Netrin-1 signaling, including DCC [66]. Additionally, gene-based tests found that depressive symptoms among participants in the UK Biobank (n = 99,057) were associated with six genes, including DCC [67]. Another UK Biobank (n = 122,935) gene-based analysis found associations between suicidality and five genes, including DCC [68]. Finally, a GWAS meta-analysis of 135,458 individuals with major depression and 344,901 controls identified 44 genomic loci significantly associated with depression, including an intronic DCC SNP (rs11663393) [69].

The above associations might reflect an effect on mood instability, a clinical feature common to numerous psychiatric disorders [70]. In a GWAS study of 60,443 controls and 53,525 mood instability cases, genome-wide significance was detected for four independent genetic loci, including an intronic DCC SNP (rs8084280) [71]. In line with this idea, genetic correlations, which assess the degree of shared heritability between phenotypes, were identified between mood instability and three psychiatric conditions: major depressive disorder, schizophrenia, and anxiety disorder [71].

Recently, a UK Biobank study (n = ~6400) found that the SNPs in the Netrin-1 signaling pathway conferring risk for major depression are associated with altered white matter microstructure in thalamic radiations, namely lower fractional anisotropy and higher mean diffusivity [72].

Strikingly, a UK Biobank meta-GWAS (n = 375,275) identified an association between anhedonia and a locus in DCC, which was the most statistically significant finding [73]. The authors also reported high genetic correlations between anhedonia and depression, as well as a moderate genetic correlation with schizophrenia [73]. Moreover, a higher anhedonia polygenic score predicted reduced brain volumes, including in the NAcc and mPFC, as well as altered white matter integrity in multiple pathways [73].

Furthermore, a genome-wide methylation study of 150 pairs of monozygotic twins (one co-twin with, and one without, early onset major depression), identified altered methylation in Netrin-1, among other genes in depression [74]. An additional meta-GWAS study reported that a Netrin-1 SNP, rs8081460, was associated with neuroticism (which is highly genetically correlated with depression) in the UK Biobank sample (n = 91,370), although this SNP effect did not replicate in two smaller, independent samples (n = 6659 and n = 8687) [75].

The larger number of studies implicating DCC, relative to Netrin-1, variants is notable. We propose that changes in receptor expression/function, including DCC, result in modifications in Netrin-1′s actions (attracting or repelling). Therefore, subtle spatiotemporal variation in DCC expression could be sufficient to produce changes in connectivity, even if total Netrin-1 expression is unaltered [6].

In the largest cross-disorder meta-GWAS of neuropsychiatric disorders to date, comprising more than 232,964 cases and 494,162 controls across eight disorders, the intronic DCC SNP, rs8084351, had the most robust pleiotropic effects [76]. This striking finding indicates that the effects of DCC and Netrin-1 are important across a wide variety of psychiatric disorders.

DCC haploinsufficiency: personality traits and drug-related behaviors

While GWAS studies typically detect relatively subtle effects of DCC polymorphisms [77], loss-of-function haploinsufficient DCC mutation carriers were expected to exhibit larger effects, detectable with smaller sample sizes. Our group recently conducted neuroimaging and psychological studies of a large Quebec family (n = 36), half of whom possess a heterozygous frameshift mutation to DCC (NM_005215.3, c.1140 + 1 G > A). The resulting mutated allele encodes a truncated DCC protein that fails to bind to Netrin-1 [78]. As in Dcc haploinsufficient mice, robust anatomical and behavioral phenotypes are observed as a consequence of human DCC haploinsufficiency, underscoring the sensitivity of the system. The DCC haploinsufficient Quebecers have an adult behavioral phenotype that shares two striking features with adult Dcc haploinsufficient mice [79]. First, the adult DCC haploinsufficient humans exhibit reduced novelty seeking personality traits [79]. Second, compared with their unaffected relatives, the DCC haploinsufficient humans smoke less tobacco yet use similar amounts of alcohol and cannabis [79], consistent with the evidence in mice that DCC’s effects are specific to stimulant drugs. Notably, cigarette smoking increases dopamine transmission in humans [80] while lowered dopaminergic tone can decrease smoking [81], indicating that an altered smoking phenotype could reflect alterations to the dopamine system.

These findings are bolstered by a large meta-GWAS (n = 518,633), which identified associations between an intronic DCC SNP, rs1221976, and self-reported “ever smoker” [82]. This finding was part of a larger study on risk-tolerance, whereby DCC SNPs were also associated with “adventurousness”, defined as the propensity to be “adventurous versus cautious.” An additional UK Biobank GWAS study (n ~ 458,000) identified an intronic DCC SNP, rs12970816, associated with cigarette smoking status [83]. Finally, one more study (discovery: n = 5339, replication: n = 1682) reported that the intronic DCC SNP, rs1372626, while not genome-wide significant, was the SNP most strongly associated with cigarette smoking, and was plausibly underpowered [84].

Moreover, in a human multivariate investigation, using a powerful and sensitive alternative to traditional SNP studies, DCC was among the top genes associated with impulsivity (n = 426) [85]. Since diminished novelty seeking is associated with reduced dopamine release in the ventral striatum of humans and rodents [14, 86, 87] these behavioral alterations might reflect DCC’s effects on mesocorticolimbic dopamine development and striatal dopamine transmission [42].

DCC haploinsufficiency: dopamine mesocorticolimbic connectivity

The associations between DCC and psychiatric disorders might be a consequence of DCC-related alterations to mesocorticolimbic pathways. As predicted, our group revealed that DCC haploinsufficient members of the Quebec family, as compared with control groups without the mutation (i.e., both relatives and unrelated healthy volunteers) exhibit striking reductions in anatomical connectivity, assessed using diffusion MRI probabilistic tractography, from the SN/VTA to both the ventral striatum and ventral mPFC [79].

These effects might include changes to dopamine pathways, but some caution is warranted. First, the reduced mesocortical connectivity differs from the increased cortical dopamine innervation seen in adult Dcc haploinsufficient mice. Second, MRI methodologies do not discern the underlying neurochemistry. Indeed, since mesocorticolimbic pathways contain dopamine, gamma-aminobutyric acid (GABA) and glutamate axons [88], the anatomical connectivity findings in humans plausibly represent alterations to both dopaminergic and non-dopaminergic axons. These same considerations also raise the possibility that the dopamine focused studies in rodents have yet to identify alterations to inter-connected non-dopamine neurons.

In rodents, there is a complementary receptor to ligand expression pattern of DCC and Netrin-1 in the NAcc and PFC. While dopamine axons express high DCC levels in the NAcc, they only rarely express DCC in the PFC [45]. Conversely, the intensity of Netrin-1 expression in the NAcc is low, especially compared to the PFC, where Netrin-1 expression is substantial [45]. Indeed, dopamine axons expressing high levels of DCC target the NAcc and do not continue to grow to the PFC in adolescence [8]. In the case of Dcc haploinsufficiency, since DCC expression is reduced, mesolimbic dopamine axons fail to recognize the NAcc as their final target and instead continue to grow ectopically into the PFC throughout adolescence [8]. In human DCC mutation carriers with reduced mesocortical anatomical connectivity, these same effects might be occurring yet the larger distances to be covered might lead the misrouted mesocortical axons to disperse more diffusely, compared to the rodents.

Striatal brain volume

We recently reported that both DCC haploinsufficient humans and mice exhibit reduced striatal volumes. While these effects occur in the NAcc in mice, they are localized to the putamen in humans [79]. These effects were also identified in large-scale GWAS investigations. One of these GWAS studies (n = 30,717), part of the Enhancing Neuro Imaging Genetics through Meta-Analysis (ENIGMA) initiative, investigated genetic variants associated with the volumes of subcortical structures [89]. Putamen volume was associated with four genetic loci, including an intronic DCC SNP (rs62097986), in both discovery and replication cohorts [89].

Bilateral putamen volume has also been associated with an intronic SNP in DCC (rs62098013), as identified in the UK Biobank Brain Imaging Data browser (, which comprises neuroimaging GWAS data from 9,707 participants [90]. Confidence in this finding is bolstered by a more recent GWAS study that reported an additional intronic locus of DCC (rs4632195) associated with both putamen volume (n = 11,598) and schizophrenia (n = 82,315) [58]. The risk allele for schizophrenia is associated with larger putamen volumes.

Earlier work also identified larger putamen volumes among those with schizophrenia [91], consistent with the two genetic investigations that found associations between SNPs in DCC and schizophrenia [53, 56]. This observation fits well with our earlier proposal that schizophrenia is associated with increased DCC expression [53]. Moreover, in discovery (n = 905) and replication (n = 166) cohorts, variants in genes incurring risk for schizophrenia, including DCC, were associated with alterations in gray matter volumes (putamen, thalamus, temporal gyrus), resting state functional magnetic resonance imaging (rs-fMRI) signals in the mPFC, and working-memory performance [92].

These striatal volumetric effects might have implications for mood disorders as well. In depression, there are reports of decreased putamen volume [93,94,95], although some other groups have failed to replicate this finding [96] potentially reflecting small sample sizes, heterogeneity within the diagnostic category, and medication effects. Indeed, there is recent MRI evidence that, in psychotropic medication-naïve participants (n = 625), elevated putamen gray matter volume is a disease risk marker across multiple diagnostic categories, namely schizophrenia, major depression, obsessive compulsive disorder, and post-traumatic stress disorder [97].

Cortical volume

The DCC haploinsufficient Quebecers also demonstrate modest volumetric increases in two cortical regions: the mPFC/anterior cingulate cortex and the ventral mPFC [79]. In comparison, among human carriers of another DCC mutation, a completely different phenotype is observed, such that there is a complete absence of the cingulate gyrus [98]. Volumetric cortical changes are not observed in Dcc haploinsufficient mice [79] and have not been identified in human neuroimaging GWAS investigations, to the authors’ knowledge, and therefore, the cortical findings may have limited generalizability.

Identification of different DCC SNPs

The effects reported here are related to multiple SNPs (Fig. 2). This could reflect several factors, including linkage disequilibrium, the set of SNPs examined, the genetic compositions of samples, the statistical procedures, the sample sizes (i.e., statistical power), and the differing use of covariates. Of note, 85% of the discussed DCC SNPs are intronic, indicating that they plausibly influence splicing, and consequently, DCC mRNA transcription and translation; [99] such intronic SNPs may affect enhancers or repressors which may distally regulate DCC transcription [100].

Fig. 2

Single nucleotide polymorphisms (SNPs) and associated phenotypes in the DCC gene. Depicted here is the 5′−3′ oriented DCC gene, comprising 29 exons (red), intervening introns (gray), untranslated regions (UTR; teal), transcriptional start site (TSS) region, promoter region, start codon (ATG) and stop codon. The rs ID for each SNP and associated phenotype(s) are indicated. The phenotypes are cross disorder (yellow), smoking (light green), depression (blue), schizophrenia (dark green), mood instability (orange), and putamen volume (purple). The gene structure and SNP locations were determined using the NCBI tool, Variation Viewer (, using the genome assembly, GRCh38.p12


This review highlights accumulating evidence that Netrin-1 and its receptor DCC contribute to mesocorticolimbic dopamine related psychiatric disorders that emerge during adolescence (Tables 1 and 2). The findings are strikingly convergent across heterogenous methodologies and samples and both between and within studies in humans and mice.

Table 1 Summary of human genetic studies of DCC and Netrin-1
Table 2 Summary of DCC and Netrin-1 effects across brain regions


  1. 1.

    Murre JMJ, Sturdy DPF. The connectivity of the brain: multi-level quantitative analysis. Biol Cyber. 1995;73:529–45.

    CAS  Article  Google Scholar 

  2. 2.

    Dickson BJ. Molecular mechanisms of axon guidance. Science. 2002;298:1959–64.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  3. 3.

    Haber SN, Knutson B. The Reward Circuit: Linking Primate Anatomy and Human Imaging. Neuropsychopharmacology. 2010;35:4–26.

    PubMed  Article  PubMed Central  Google Scholar 

  4. 4.

    Sesack SR, Grace AA. Cortico-basal ganglia reward network: microcircuitry. Neuropsychopharmacology. 2010;35:27–47.

    PubMed  Article  PubMed Central  Google Scholar 

  5. 5.

    Yetnikoff L, Lavezzi HN, Reichard RA, Zahm DS. An update on the connections of the ventral mesencephalic dopaminergic complex. Neuroscience. 2014;282:23–48.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  6. 6.

    Flores C. Role of netrin-1 in the organization and function of the mesocorticolimbic dopamine system. J Psychiatry Neurosci. 2011;36:296–310.

    PubMed  PubMed Central  Article  Google Scholar 

  7. 7.

    Hoops D, Flores C. Making Dopamine Connections in Adolescence. Trends Neurosci. 2017;40:709–19.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  8. 8.

    Reynolds LM, Pokinko M, Berrío AT, Cuesta S, Lambert LC, Pellitero EDC, et al. DCC receptors drive prefrontal cortex maturation by determining dopamine axon targeting in adolescence. Biol Psychiatry. 2018;83:181–92.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  9. 9.

    Düzel E, Bunzeck N, Guitart-Masip M, Wittmann B, Schott BH, Tobler PN. Functional imaging of the human dopaminergic midbrain. Trends Neurosci. 2009;32:321–8.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  10. 10.

    Lewis DA, Melchitzky DS, Sesack SR, Whitehead RE, Auh S, Sampson A. Dopamine transporter immunoreactivity in monkey cerebral cortex: regional, laminar, and ultrastructural localization. J Comp Neurol. 2001;432:119–36.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  11. 11.

    Taber KH, Black DN, Porrino LJ, Hurley RA. Neuroanatomy of dopamine: reward and addiction. J Neuropsychiatry Clin Neurosci. 2012;24:1–4.

    PubMed  Article  PubMed Central  Google Scholar 

  12. 12.

    Horga G, Cassidy CM, Xu X, Moore H, Slifstein M, Van Snellenberg JX, et al. Dopamine-related disruption of functional topography of striatal connections in unmedicated patients with schizophrenia. JAMA psychiatry. 2016;73:862–70.

    PubMed  PubMed Central  Article  Google Scholar 

  13. 13.

    Kohno M, Morales AM, Ghahremani DG, Hellemann G, London ED. Risky decision making, prefrontal cortex, and mesocorticolimbic functional connectivity in methamphetamine dependence. JAMA Psychiatry. 2014;71:812–20.

    PubMed  PubMed Central  Article  Google Scholar 

  14. 14.

    Leyton M, Vezina P. Dopamine ups and downs in vulnerability to addictions: a neurodevelopmental model. Trends Pharm Sci. 2014;35:268–76.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  15. 15.

    Furman DJ, Hamilton JP, Gotlib IH. Frontostriatal functional connectivity in major depressive disorder. Biol mood anxiety Disord. 2011;1:1–11.

    Article  Google Scholar 

  16. 16.

    Russo SJ, Nestler EJ. The brain reward circuitry in mood disorders. Nat Rev Neurosci. 2013;14:609–25.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  17. 17.

    Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62:593–602.

    PubMed  Article  PubMed Central  Google Scholar 

  18. 18.

    Kessler RC, Amminger GP, Aguilar-Gaxiola S, Alonso J, Lee S, Ustun TB. Age of onset of mental disorders: a review of recent literature. Curr Opin Psychiatry. 2007;20:359–64.

    PubMed  PubMed Central  Article  Google Scholar 

  19. 19.

    Reynolds LM, Flores C. Guidance cues: linking drug use in adolescence with psychiatric disorders. Neuropsychopharmacology. 2019;44:225–6.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  20. 20.

    Dent EW, Gupton SL, Gertler FB. The Growth Cone Cytoskeleton in Axon Outgrowth and Guidance. Cold Spring Harb Perspect Biol. 2011;3:a001800.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  21. 21.

    Van Battum EY, Brignani S, Pasterkamp RJ. Axon guidance proteins in neurological disorders. Lancet Neurol. 2015;14:532–46.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  22. 22.

    Mawdsley DJ, Cooper HM, Hogan BM, Cody SH, Lieschke GJ, Heath JK. The Netrin receptor Neogenin is required for neural tube formation and somitogenesis in zebrafish. Dev Biol. 2004;269:302–15.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  23. 23.

    Finci LI, Krüger N, Sun X, Zhang J, Chegkazi M, Wu Y, et al. The crystal structure of netrin-1 in complex with DCC reveals the bifunctionality of netrin-1 as a guidance cue. Neuron. 2014;83:839–49.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  24. 24.

    Ly A, Nikolaev A, Suresh G, Zheng Y, Tessier-Lavigne M, Stein E. DSCAM is a netrin receptor that collaborates with DCC in mediating turning responses to netrin-1. Cell. 2008;133:1241–54.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  25. 25.

    Brennaman LH, Maness PF. Developmental regulation of GABAergic interneuron branching and synaptic development in the prefrontal cortex by soluble neural cell adhesion molecule. Mol Cell Neurosci. 2008;37:781–93.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  26. 26.

    Barnes SH, Price SR, Wentzel C, Guthrie SC. Cadherin-7 and cadherin-6B differentially regulate the growth, branching and guidance of cranial motor axons. Development. 2010;137:805–14.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  27. 27.

    Schmeisser MJ, Baumann B, Johannsen S, Vindedal GF, Jensen V, Hvalby ØC, et al. IκB kinase/nuclear factor κB-dependent insulin-like growth factor 2 (Igf2) expression regulates synapse formation and spine maturation via Igf2 receptor signaling. J Neurosci. 2012;32:5688–703.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  28. 28.

    Szebenyi G, Dent EW, Callaway JL, Seys C, Lueth H, Kalil K. Fibroblast growth factor-2 promotes axon branching of cortical neurons by influencing morphology and behavior of the primary growth cone. J Neurosci. 2001;21:3932–41.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  29. 29.

    Ebens A, Brose K, Leonardo ED, Hanson MG Jr, Bladt F, Birchmeier C, et al. Hepatocyte growth factor/scatter factor is an axonal chemoattractant and a neurotrophic factor for spinal motor neurons. Neuron. 1996;17:1157–72.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  30. 30.

    Boyer NP, Gupton SL. Revisiting Netrin-1: one who guides (axons). Front Cell Neurosci. 2018;12:1–18.

    Article  CAS  Google Scholar 

  31. 31.

    Brankatschk M, Dickson BJ. Netrins guide Drosophila commissural axons at short range. Nat Neurosci. 2006;9:188–94.

    CAS  PubMed  Article  Google Scholar 

  32. 32.

    Teichmann HM, Shen K. UNC-6 and UNC-40 promote dendritic growth through PAR-4 in Caenorhabditis elegans neurons. Nat Neurosci. 2011;14:165–72.

    CAS  PubMed  Article  Google Scholar 

  33. 33.

    Glasgow SD, Labrecque S, Beamish IV, Aufmkolk S, Gibon J, Han D, et al. Activity-Dependent Netrin-1 Secretion Drives Synaptic Insertion of GluA1-Containing AMPA Receptors in the Hippocampus. Cell Rep. 2018;25:168–182 e166.

    CAS  PubMed  Article  Google Scholar 

  34. 34.

    Hedrick L, Cho KR, Fearon ER, Wu T-C, Kinzler KW, Vogelstein B. The DCC gene product in cellular differentiation and colorectal tumorigenesis. Genes Dev. 1994;8:1174–83.

    CAS  PubMed  Article  Google Scholar 

  35. 35.

    Finci LI, Krüger N, Sun X, Zhang J, Chegkazi M, Wu Y, et al. The crystal structure of netrin-1 in complex with DCC reveals the bi-functionality of netrin-1 as a guidance cue. Neuron. 2014;83:839–49.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  36. 36.

    Cho KR, Oliner JD, Simons JW, Hedrick L, Fearon ER, Preisinger AC, et al. The DCC gene: structural analysis and mutations in colorectal carcinomas. Genomics. 1994;19:525–31.

    CAS  PubMed  Article  Google Scholar 

  37. 37.

    Keino-Masu K, Masu M, Hinck L, Leonardo ED, Chan SS, Culotti JG, et al. Deleted in Colorectal Cancer (DCC) encodes a netrin receptor. Cell. 1996;87:175–85.

    CAS  PubMed  Article  Google Scholar 

  38. 38.

    Gad JM, Keeling SL, Wilks AF, Tan S-S, Cooper HM. The expression patterns of guidance receptors, DCC and Neogenin, are spatially and temporally distinct throughout mouse embryogenesis. Dev Biol. 1997;192:258–73.

    CAS  PubMed  Article  Google Scholar 

  39. 39.

    Harter P, Bunz B, Dietz K, Hoffmann K, Meyermann R, Mittelbronn M. Spatio-temporal deleted in colorectal cancer (DCC) and netrin-1 expression in human foetal brain development. Neuropathol Appl Neurobiol. 2010;36:623–35.

    CAS  PubMed  Article  Google Scholar 

  40. 40.

    Livesey F, Hunt S. Netrin and netrin receptor expression in the embryonic mammalian nervous system suggests roles in retinal, striatal, nigral, and cerebellar development. Mol Cell Neurosci. 1997;8:417–29.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  41. 41.

    Osborne P, Halliday G, Cooper H, Keast J. Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents. Neuroscience. 2005;131:671–81.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  42. 42.

    Grant A, Hoops D, Labelle‐Dumais C, Prévost M, Rajabi H, Kolb B, et al. Netrin-1 receptor-deficient mice show enhanced mesocortical dopamine transmission and blunted behavioural responses to amphetamine. Eur J Neurosci. 2007;26:3215–28.

    PubMed  Article  PubMed Central  Google Scholar 

  43. 43.

    Manitt C, Labelle-Dumais C, Eng C, Grant A, Mimee A, Stroh T, et al. Peri-pubertal emergence of UNC-5 homologue expression by dopamine neurons in rodents. PLoS ONE. 2010;5:e11463.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44.

    Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, et al. Trophic factors differentiate dopamine neurons vulnerable to Parkinson’s disease. Neurobiol Aging. 2013;34:873–86.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  45. 45.

    Manitt C, Mimee A, Eng C, Pokinko M, Stroh T, Cooper HM, et al. The netrin receptor DCC is required in the pubertal organization of mesocortical dopamine circuitry. J Neurosci. 2011;31:8381–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  46. 46.

    Flores C, Manitt C, Rodaros D, Thompson K, Rajabi H, Luk K, et al. Netrin receptor deficient mice exhibit functional reorganization of dopaminergic systems and do not sensitize to amphetamine. Mol Psychiatry. 2005;10:606–12.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  47. 47.

    Reynolds LM, Yetnikoff L, Pokinko M, Wodzinski M, Epelbaum JG, Lambert LC, et al. Early Adolescence is a Critical Period for the Maturation of Inhibitory Behavior. Cerebral Cortex. 2018;29:1–11.

  48. 48.

    Pokinko M, Moquin L, Torres-Berrío A, Gratton A, Flores C. Resilience to amphetamine in mouse models of netrin-1 haploinsufficiency: role of mesocortical dopamine. Psychopharmacology. 2015;232:3719–29.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  49. 49.

    Kim JH, Lavan D, Chen N, Flores C, Cooper H, Lawrence AJ. Netrin-1 receptor-deficient mice show age-specific impairment in drug-induced locomotor hyperactivity but still self-administer methamphetamine. Psychopharmacology. 2013;230:607–16.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  50. 50.

    Reynolds LM, Gifuni AJ, McCrea ET, Shizgal P, Flores C. dcc haploinsufficiency results in blunted sensitivity to cocaine enhancement of reward seeking. Behav Brain Res. 2016;298:27–31.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  51. 51.

    Horn KE, Glasgow SD, Gobert D, Bull S-J, Luk T, Girgis J, et al. DCC expression by neurons regulates synaptic plasticity in the adult brain. Cell Rep. 2013;3:173–85.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  52. 52.

    Cuesta S, Restrepo-Lozano JM, Popescu C, He S, Reynolds LM, Israel S et al. DCC-related developmental effects of abused-versus therapeutic-like amphetamine doses in adolescence. Addiction Biol. 2019:e12791.

  53. 53.

    Grant A, Fathalli F, Rouleau G, Joober R, Flores C. Association between schizophrenia and genetic variation in DCC: a case–control study. Schizophr Res. 2012;137:26–31.

    PubMed  Article  PubMed Central  Google Scholar 

  54. 54.

    Torres-Berrío A, Lopez JP, Bagot RC, Nouel D, Dal Bo G, Cuesta S, et al. DCC confers susceptibility to depression-like behaviors in humans and mice and is regulated by miR-218. Biol Psychiatry. 2017;81:306–15.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  55. 55.

    Lewis BP, Shih I-h, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115:787–98.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  56. 56.

    Yan P, Qiao X, Wu H, Yin F, Zhang J, Ji Y, et al. An association study between genetic polymorphisms in functional regions of five genes and the risk of Schizophrenia. J Mol Neurosci. 2016;59:366–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  57. 57.

    Schmitt C, Thaler K, Wittig B, Kaulen H, zum Büschenfelde KM, Dippold W. Detection of the DCC gene product in normal and malignant colorectal tissues and its relation to a codon 201 mutation. Br J Cancer. 1998;77:588–94.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  58. 58.

    Smeland OB, Wang Y, Frei O, Li W, Hibar DP, Franke B, et al. Genetic overlap between schizophrenia and volumes of hippocampus, putamen, and intracranial volume indicates shared molecular genetic mechanisms. Schizophr Bull. 2018;44:854–64.

    PubMed  Article  PubMed Central  Google Scholar 

  59. 59.

    Okayama T, Hashiguchi Y, Kikuyama H, Yoneda H, Kanazawa T. Next-generation sequencing analysis of multiplex families with atypical psychosis. Transl Psychiatry. 2018;8:1–7.

    CAS  Article  Google Scholar 

  60. 60.

    Manitt C, Eng C, Pokinko M, Ryan R, Torres-Berrio A, Lopez J, et al. DCC orchestrates the development of the prefrontal cortex during adolescence and is altered in psychiatric patients. Transl Psychiatry. 2013;3:1–13.

    Article  CAS  Google Scholar 

  61. 61.

    Leday GG, Vértes PE, Richardson S, Greene JR, Regan T, Khan S, et al. Replicable and coupled changes in innate and adaptive immune gene expression in two case-control studies of blood microarrays in major depressive disorder. Biol Psychiatry. 2018;83:70–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  62. 62.

    Aberg KA, Shabalin AA, Chan RF, Zhao M, Kumar G, van Grootheest G, et al. Convergence of evidence from a methylome-wide CpG-SNP association study and GWAS of major depressive disorder. Transl Psychiatry. 2018;8:1–10.

    CAS  Article  Google Scholar 

  63. 63.

    Yu L, Chibnik LB, Yang J, McCabe C, Xu J, Schneider JA, et al. Methylation profiles in peripheral blood CD4+ lymphocytes versus brain: The relation to Alzheimer’s disease pathology. Alzheimer’s Dement. 2016;12:942–51.

    Article  Google Scholar 

  64. 64.

    Dunn EC, Wiste A, Radmanesh F, Almli LM, Gogarten SM, Sofer T, et al. Genome-wide association study (GWAS) and genome‐wide by environment interaction study (GWEIS) of depressive symptoms in African American and Hispanic/Latina women. Depress Anxiety. 2016;33:265–80.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  65. 65.

    Okbay A, Baselmans BM, De Neve J-E, Turley P, Nivard MG, Fontana MA, et al. Genetic variants associated with subjective well-being, depressive symptoms, and neuroticism identified through genome-wide analyses. Nat Genet. 2016;48:624–33.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  66. 66.

    Zeng Y, Navarro P, Fernandez-Pujals AM, Hall LS, Clarke T-K, Thomson PA, et al. A combined pathway and regional heritability analysis indicates NETRIN1 pathway is associated with major depressive disorder. Biol Psychiatry. 2017;81:336–46.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  67. 67.

    Arnau-Soler A, Macdonald-Dunlop E, Adams MJ, Clarke T-K, MacIntyre DJ, Milburn K, et al. Genome-wide by environment interaction studies of depressive symptoms and psychosocial stress in UK Biobank and Generation Scotland. Transl Psychiatry. 2019;9:1–13.

    CAS  Article  Google Scholar 

  68. 68.

    Strawbridge RJ, Ward J, Ferguson A, Graham N, Shaw RJ, Cullen B, et al. Identification of novel genome-wide associations for suicidality in UK Biobank, genetic correlation with psychiatric disorders and polygenic association with completed suicide. EBioMedicine. 2019;41:517–25.

    PubMed  PubMed Central  Article  Google Scholar 

  69. 69.

    Wray NR, Ripke S, Mattheisen M, Trzaskowski M, Byrne EM, Abdellaoui A, et al. Genome-wide association analyses identify 44 risk variants and refine the genetic architecture of major depression. Nat Genet. 2018;50:668–81.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  70. 70.

    Broome MR, Saunders KEA, Harrison PJ, Marwaha S. Mood instability: significance, definition and measurement. Br J Psychiatry. 2015;207:283–5.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  71. 71.

    Ward J, Strawbridge RJ, Bailey ME, Graham N, Ferguson A, Lyall DM, et al. Genome-wide analysis in UK Biobank identifies four loci associated with mood instability and genetic correlation with major depressive disorder, anxiety disorder and schizophrenia. Transl Psychiatry. 2017;7:1–9.

    Article  Google Scholar 

  72. 72.

    Barbu MC, Zeng Y, Shen X, Cox SR, Clarke T-K, Gibson J, et al. Association of whole-genome and NETRIN1 signaling pathway–derived polygenic risk scores for major depressive disorder and white matter microstructure in the UK Biobank. Biol Psychiatry: Cogn Neurosci Neuroimaging. 2019;4:91–100.

    Google Scholar 

  73. 73.

    Ward J, Lyall L, Bethlehem RA, Ferguson AA, Strawbridge RJ, Lyall DM, et al. Novel genome-wide associations for anhedonia, genetic correlation with psychiatric disorders, and polygenic association with brain structure. bioRxiv. 2019:656298.

  74. 74.

    Roberson-Nay R, Wolen AR, Lapato DM, Lancaster EE, Webb BT, Verhulst B, et al. Twin Study of Early-Onset Major Depression Finds DNA Methylation Enrichment for Neurodevelopmental Genes. bioRxiv. 2018:422345.

  75. 75.

    Smith DJ, Escott-Price V, Davies G, Bailey MES, Colodro-Conde L, Ward J, et al. Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci. Mol Psychiatry. 2016;21:749–57.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  76. 76.

    Lee PH, Anttila V, Won H, Feng Y-CA, Rosenthal J, Zhu Z, et al. Genome wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders. bioRxiv. 2019:528117.

  77. 77.

    Manolio TA, Collins FS, Cox NJ, Goldstein DB, Hindorff LA, Hunter DJ, et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747–53.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  78. 78.

    Srour M, Riviere JB, Pham JM, Dube MP, Girard S, Morin S, et al. Mutations in DCC cause congenital mirror movements. Science. 2010;328:592–592.

    CAS  PubMed  Article  Google Scholar 

  79. 79.

    Vosberg DE, Zhang Y, Menegaux A, Chalupa A, Manitt C, Zehntner S, et al. Mesocorticolimbic connectivity and volumetric alterations in DCC mutation carriers. J Neurosci. 2018;38:4655–65.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  80. 80.

    Wing VC, Payer DE, Houle S, George TP, Boileau I. Measuring cigarette smoking-induced cortical dopamine release: a [11C]FLB-457 PET study. Neuropsychopharmacology. 2014;40:1417–27.

    PubMed  Article  CAS  PubMed Central  Google Scholar 

  81. 81.

    Venugopalan VV, Casey KF, O’Hara C, O’Loughlin J, Benkelfat C, Fellows LK, et al. Acute phenylalanine/tyrosine depletion reduces motivation to smoke cigarettes across stages of addiction. Neuropsychopharmacology. 2011;36:2469–76.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  82. 82.

    Linnér RK, Biroli P, Kong E, Meddens SFW, Wedow R, Fontana MA, et al. Genome-wide association analyses of risk tolerance and risky behaviors in over 1 million individuals identify hundreds of loci and shared genetic influences. Nat Genet. 2019;51:245–57.

    PubMed Central  Article  CAS  Google Scholar 

  83. 83.

    Kichaev G, Bhatia G, Loh P-R, Gazal S, Burch K, Freund MK, et al. Leveraging polygenic functional enrichment to improve GWAS power. Am J Hum Genet. 2019;104:65–75.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  84. 84.

    Zanetti KA, Wang Z, Aldrich M, Amos CI, Blot WJ, Bowman ED, et al. Genome-wide association study confirms lung cancer susceptibility loci on chromosomes 5p15 and 15q25 in an African-American population. Lung Cancer. 2016;98:33–42.

    PubMed  PubMed Central  Article  Google Scholar 

  85. 85.

    Khadka S, Narayanan B, Meda SA, Gelernter J, Han S, Sawyer B, et al. Genetic association of impulsivity in young adults: a multivariate study. Transl Psychiatry. 2014;4:e451.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  86. 86.

    Leyton M, Boileau I, Benkelfat C, Diksic M, Baker G, Dagher A. Amphetamine-induced increases in extracellular dopamine, drug wanting, and novelty seeking: a PET/[11C] raclopride study in healthy men. Neuropsychopharmacology. 2002;27:1027–35.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  87. 87.

    Jaworska N, Cox SM, Casey KF, Boileau I, Cherkasova M, Larcher K, et al. Is there a relation between novelty seeking, striatal dopamine release and frontal cortical thickness? PLoS ONE. 2017;12:e0174219.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88.

    Morales M, Pickel VM. Insights to drug addiction derived from ultrastructural views of the mesocorticolimbic system. Ann N Y Acad Sci. 2012;1248:71–88.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  89. 89.

    Hibar DP, Stein JL, Renteria ME, Arias-Vasquez A, Desrivières S, Jahanshad N, et al. Common genetic variants influence human subcortical brain structures. Nature. 2015;520:224–9.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  90. 90.

    Elliott LT, Sharp K, Alfaro-Almagro F, Shi S, Miller KL, Douaud G, et al. Genome-wide association studies of brain imaging phenotypes in UK Biobank. Nature. 2018;562:210–6.

  91. 91.

    Okada N, Fukunaga M, Yamashita F, Koshiyama D, Yamamori H, Ohi K, et al. Abnormal asymmetries in subcortical brain volume in schizophrenia. Mol Psychiatry. 2016;21:1460–6.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  92. 92.

    Luo N, Sui J, Chen J, Zhang F, Tian L, Lin D, et al. A Schizophrenia-Related Genetic-Brain-Cognition Pathway Revealed in a Large Chinese Population. EBioMedicine. 2018;37:471–82.

    PubMed  PubMed Central  Article  Google Scholar 

  93. 93.

    Sachs-Ericsson NJ, Hajcak G, Sheffler JL, Stanley IH, Selby EA, Potter GG, et al. Putamen volume differences among older adults: depression status, melancholia, and age. J Geriatr Psychiatry Neurol. 2017;31:39–49.

    Article  Google Scholar 

  94. 94.

    Koolschijn P, van Haren NE, Lensvelt-Mulders GJ, Pol H, Hilleke E, Kahn RS. Brain volume abnormalities in major depressive disorder: a meta-analysis of magnetic resonance imaging studies. Hum Brain Mapp. 2009;30:3719–35.

    Article  Google Scholar 

  95. 95.

    Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM. Magnetic resonance imaging studies in unipolar depression: systematic review and meta-regression analyses. Eur Neuropsychopharmacol. 2012;22:1–16.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  96. 96.

    Schmaal L, Veltman DJ, van Erp TG, Sämann P, Frodl T, Jahanshad N, et al. Subcortical brain alterations in major depressive disorder: findings from the ENIGMA Major Depressive Disorder working group. Mol Psychiatry. 2016;21:806–12.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

  97. 97.

    Gong Q, Scarpazza C, Dai J, He M, Xu X, Shi Y, et al. A transdiagnostic neuroanatomical signature of psychiatric illness. Neuropsychopharmacology. 2019;44:869–75.

    PubMed  Article  PubMed Central  Google Scholar 

  98. 98.

    Edwards TJ, Marsh APL, Lockhart PJ, Richards LJ, Leventer RJ. Teaching NeuroImages: Imaging features of DCC-mediated mirror movements and isolated agenesis of the corpus callosum. Neurology. 2018;91:e886–7.

    PubMed  Article  PubMed Central  Google Scholar 

  99. 99.

    Cooper DN. Functional intronic polymorphisms: buried treasure awaiting discovery within our genes. Hum Genomics. 2010;4:284–8.

    PubMed  PubMed Central  Article  Google Scholar 

  100. 100.

    Schoenfelder S, Fraser P. Long-range enhancer–promoter contacts in gene expression control. Nat Rev Genet. 2019;20:437–55.

    CAS  PubMed  Article  PubMed Central  Google Scholar 

Download references


CF is supported by the National Institute on Drug Abuse (R01DA037911), the Natural Science and Engineering Research Council of Canada (2982226), and Canadian Institutes of Health Research (MOP-74709, 119543). ML is supported by three grants from the Canadian Institutes of Health Research (MOP-119543, 133537, 152910). DEV received scholarship support from Le Fonds de recherche du Québec – Santé (FRQS) and McGill University Faculty of Medicine Internal Studentship Awards (the Hugh E. Burke Fellowship and the James O. and Maria Meadows Fellowship). We would like to acknowledge Drs. Tomáš Paus and Patricia Pelufo Silveira for their feedback on an earlier version of the manuscript and Drs. Alanna Grant and Lauren Reynolds for their advice on figure preparation.

Author information




DEV, ML, and CF all contributed to the writing, literature search, and conception of the figures. DEV generated the figures.

Corresponding authors

Correspondence to Marco Leyton or Cecilia Flores.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Vosberg, D.E., Leyton, M. & Flores, C. The Netrin-1/DCC guidance system: dopamine pathway maturation and psychiatric disorders emerging in adolescence. Mol Psychiatry 25, 297–307 (2020).

Download citation

Further reading


Quick links